<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An Epstein-Barr virus (EBV)-specific DNase was induced in EBV nonproducer Raji cells after treatment with 12-O-tetradecanoylphorbol-13-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> and <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The increase in EBV DNase activity was related to the appearance of early antigen-positive cells </plain></SENT>
<SENT sid="2" pm="."><plain>The enzyme had a sedimentation coefficient of 4S and was resistant to 300 mM <z:chebi fb="0" ids="32588">KCl</z:chebi>, and its induction did not depend on <z:mp ids='MP_0001799'>viral</z:mp> DNA synthesis </plain></SENT>
<SENT sid="3" pm="."><plain>The EBV-specific DNase activity was specifically inhibited by sera from patients who had nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> with high early antigen activities but not by sera from <z:mpath ids='MPATH_458'>normal</z:mpath>, healthy individuals </plain></SENT>
<SENT sid="4" pm="."><plain>There was a correlation between the degree of anti-EBV DNase activity and the titers of early antigen antibody </plain></SENT>
</text></document>